Overview

Gender

male

Charles Rowland is the Chief Executive Officer at Aurinia Pharmaceuticals and has more than 30 years of experience in financial management and strategic business operations.

Charles served as the Vice President and Chief Financial Officer at ViroPharma Incorporated, an international biopharmaceutical company, until it was acquired by Shire plc in January 2014. Charles also served as Senior Vice President of Finance, with responsibilities for leading the treasury, tax, investor relations and business planning groups.

Prior to joining ViroPharma in 2008, Charles was the Executive Vice President and Chief Financial Officer, as well as the Interim Co-Chief Executive Officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management, where he served from 2006 to 2008. At Endo, Charles drove the strategic planning process, including the design and implementation of the company’s mid and long-term strategy. From 2004 to 2006, Charles was the Senior Vice President and Chief Financial Officer at Biovail Corporation, an international pharmaceutical company, where he directed all financial activities for the company including tax, treasury, accounting, financial analysis, investor relations as well as all aspects of information technology.

Charles previously held positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co.

Charles holds MBA from Rutgers University and B.S. degree in Accounting from Saint Joseph's University.